Ilaris® (canakinumab)

Ilaris (canakinumab) is covered only for its FDA‑approved indications — CAPS, TRAPS, HIDS/MKD, FMF, active sJIA (≥2 years), adult‑onset Still’s disease, and gout flares — subject to condition‑specific age limits. Coverage requires specialist prescribing/consultation, specified prior therapy trials (e.g., colchicine for FMF, ≥2 biologics for sJIA/Still’s where required), baseline CRP and flare‑frequency or hospitalization criteria as applicable, initial authorization for 6 months (12‑month renewals) and documented objective or symptomatic improvement for reauthorization.

"Gout Flares"

Sign up to see full coverage criteria, indications, and limitations.